"9. MannKind Corp. (MNKD, Earnings, Analysts, Financials): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $611.99M, most recent closing price at $2.49.Of the 6 analysts that have set a target price on the stock, the lowest price target stands at $3. This implies a potential upside of 15.83% from current levels around $2.59."

http://wire.kapitall.com/investment-idea/11-stocks-under-5-trading-at-discounts-to-target-price/